{"id":"W3088602042","doi":"10.1016/j.annonc.2020.08.2250","title":"LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; PTEN; Prostate cancer; Internal medicine; Placebo; Androgen deprivation therapy; Prednisone; Gastroenterology; Asymptomatic; Clinical endpoint; Cancer; Urology; Oncology; Clinical trial; PI3K/AKT/mTOR pathway; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005843771,0.0003159026,0.001359544,0.0002780438,0.00007187156,0.00001471113,0.0002169268,0.0001159394,0.0004677617],"category_scores_gemma":[0.0001223944,0.000254128,0.0001260572,0.000610548,0.0002620844,0.0001752403,0.0001158594,0.0003519785,0.00001551765],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002819138,"about_ca_system_score_gemma":0.001974506,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004933659,"about_ca_topic_score_gemma":0.003721181,"domain_scores_codex":[0.9967318,0.0003629943,0.001157533,0.0005512275,0.000566225,0.000630287],"domain_scores_gemma":[0.9982315,0.0001580507,0.0004595713,0.0003456718,0.0004612551,0.0003439844],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4982011,0.02860685,0.02014661,0.004239819,0.005322144,0.009768855,0.1038204,0.005154873,0.2344157,0.0001445933,0.01889271,0.07128635],"study_design_scores_gemma":[0.4844339,0.2055117,0.03446238,0.001069303,0.002334624,0.00007127662,0.03481074,0.007893014,0.2142375,0.0002445269,0.01350705,0.001423953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874363,0.001715395,0.00001188227,0.006803007,0.0001371112,0.003126337,0.000403621,0.00002916866,0.0003371733],"genre_scores_gemma":[0.9970152,0.0009691151,0.00009825354,0.0005923918,0.0000798962,0.0005596924,0.0002221877,0.00003979567,0.0004234914],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1769049,"threshold_uncertainty_score":0.9999911,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1923641444501005,"score_gpt":0.4583087087033202,"score_spread":0.2659445642532197,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}